Bob Stein

SAB Member at Autobahn Labs

Dr. Robert Stein has more than 35 years of experience and accomplishments in the pharmaceutical and biotech industry. Over the course of his career, Dr. Stein has played a significant role in the discovery and development of eight marketed drugs, including Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta®, & Eliquis®. He previously served as President of Research and Development for Agenus, Inc., and has held a number of progressively responsible senior management positions including Head of Pharmacology for Merck & Co., CSO & SVP of Research for Ligand Pharmaceuticals, EVP of Research & Preclinical Development for Dupont Merck, President and CSO for Incyte Pharmaceuticals, President of Roche Palo Alto, and CEO of KineMed.

Dr. Stein spent the early part of his career at Merck, Sharp and Dohme Research Laboratories. He holds an MD and a PhD in Physiology & Pharmacology from Duke University.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Autobahn Labs

Autobahn Labs is collaboration between a Samsara BioCapital-led investor syndicate and Evotec.


Industries

Employees

1-10

Links